Anti-arthritic properties of FK506 on collagen-induced arthritis in rats

Inflammation Research

Volumn 52, Issue 12, 2003, Pages 524-529

  Magari, K ^a   Nishigaki, F ^a   Sasakawa, T ^a   Ogawa, T ^a   Miyata, S ^a   Ohkubo, Y ^a   Mutoh, S ^a   Goto, T ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Bone; Cartilage; Collagen induced arthritis; FK506; Proteoglycan; Tumor necrosis factor

Indexed keywords

COLLAGEN TYPE 2; FREUND ADJUVANT; PROTEOGLYCAN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; BONE DENSITY; BONE INJURY; BONE MINERAL; CARTILAGE DEGENERATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FEMUR HEAD; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KNEE; NONHUMAN; PAW EDEMA; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; TISSUE LEVEL; TREATMENT OUTCOME;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE; FEMALE; FEMUR; HINDLIMB; IMMUNOHISTOCHEMISTRY; JOINTS; PROTEOGLYCANS; RATS; RATS, INBRED LEW; TACROLIMUS;

EID: 0347985498     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1210-8     Document Type: Article

References (31)

1. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 1992; 35: 729-35.
2. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 151-60.
3. Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 2000; 51: 207-29.
4. Feldmann M, Maini RN. Anti-TNFα therapy of rheumatoid arthritis: What have we learned? Annu. Rev. Immunol. 2001; 19: 163-96.
5. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T et al. FK-506, a novel immunosuppressant isolated from a streptomyces II. Immunosuppressive effect of FK-506 in vitro. J. Antibiotics 1987; 40: 1256-65.
6. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J. Immunol. 1987; 139: 1797-803.
7. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J. Immunol. 1989; 143: 718-26.
8. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Clin. Immunol. Immunopathol. 1996; 80: S40-5.
9. Furst DE, Saag K, Fleishmann MR, Sherrer Y, Block JA, Schnitzer T et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate. A six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum. 2002; 46: 2020-8.
10. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S et al. FK506 potently inhibitsT cell activation induced TNF-α and IL-1β production in vitro by human peripheral blood mononuclear cells. Br. J. Pharmacol. 2000; 130: 1655-63.
11. Sakuma S, Nishigaki F, Magari K, Ogawa T, Miyata S, Ohkubo Y, Goto T. FK506 is superior to Methotrexate in therapeutic effects on advanced stage of rat adjuvant-induced arthritis. Inflamm. Res. 2001; 50: 509-14.
12. Nishigaki F, Sakuma S, Ogawa T, Miyata S, Ohkubo Y, Goto T. FK506 induces chondrogenic differentiation of clonal mouse embryonic carcinoma cells, ATDC5. Eur. J. Pharmacol. 2002; 437: 123-8.
13. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J. Exp. Med. 1977; 146: 857-68.
14. Klareskog L, Holmdahl R, Larsson E, Wigzell H. Role of T lymphocytes in collagen II induced arthritis in rats. Clin. exp. Immunol. 1983; 51: 117-25.
15. Stuart JM, Cremer MA, Townes AS, Kang AH. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. J. Exp. Med. 1982; 155: 1-16.
16. Honbo T, Kobayashi M, Hane K, Hata T, Ueda Y. The oral dosage form of FK-506. Transplant Proc 1987; 19 Suppl 6: 17-22.
17. Karran EH, Young TJ, Markwell RE, Harper GP. In vivo model of cartilage degradation - effects of a matrix metalloproteinase inhibitor. Ann. Rheum. Dis. 1995; 54: 662-9.
18. Inamura N, Hashimoto M, Nakahara K, Aoki H, Yamaguchi I, Kohsaka M. Immunosupressive effect of FK506 on collagen-induced arthritis in rats. Clin. Immunol. Immunopathol. 1988; 46: 82-90.
19. Arita C, Hotokebuchi T, Miyahara H, Arai K, Sugioka Y, Takagishi K, Kaibara, N. Effect of FK 506 (FR 900506) on collagen arthritis in rats: A preliminary report. Transplant. Proc. 1989; 21: 1056-8.
20. Akerlund K, Erlandsson-Harris H, Tracy KJ, Wang H, Fehniger T, Klareskog L et al. Antiinflammatory effects of a new tumor necrosis factor-alpha (TNF-α) inhibitor (CNI-1493) in collagen-induced arthritis (CIA) in rats. Clin. Exp. immunol. 1999; 115: 32-41.
21. Palmblad K, Erlandsson-Harris H, Tracy KJ, Andersson U. Dynamics of early synovial cytokine expression in rodent collagen-induced arthritis. A therapeutic study using a macrophage-deactivating compound. Am. J. Pathol. 2001; 158: 491-500.
22. Brahn E, Trentham DE. Effect of antithymocyte serum on collagen arthritis in rats: Evidence that T cells are involved in its pathogenesis. Cell. Immunol. 1984; 86: 421-8.
23. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis. Comparison of efficacy in animal models with human clinical data. Arthritis Rheum. 1999; 42: 498-506.
24. Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, Edwards áV CK. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 2000; 43: 2648-59.
25. Suzuki Y, Mizushima Y. Osteoporosis in rheumatoid arthritis. Osteoporosis Int. 1997; 7: S217-22.
26. Hanyu T, Chotanaphuti T, Arai K, Tanaka T, Takahashi E. Histomorphometric assessment of bone changes in rats with type II collagen-induced arthritis. Bone 1999; 24: 485-90.
27. Takagi T, Tsao PW, Totsuka R, Suzuki T, Murata T, Takata I. Dexamethasone prevents the decrease of bone mineral density in type II collagen-induced rat arthritis model. Jpn J Pharmacol. 1998; 78: 225-8.
28. Enokida M, Yamasaki D, Okano T, Hagino H, Morio Y, Teshima R. 2001. Bone mass changes of tibial and vertebral bones in young adult rats with collagen-induced arthritis. Bone 2001; 28: 87-93.
29. Manolagas SC. Role of cytokines in bone resorption. Bone 1995; 17(2 Suppl): S63-7.
30. Dayer JM, Burger D. Interleukin-1, tumor necrosis factor and their specific inhibitors. Eur Cytokine Netw. 1994; 5: 563-71.
31. Mi Z, Ghivizzani SC, Lechman ER, Jaffurs D, Glorioso JC, Evans CH, Robbins PD. Adenovirus-mediated gene transfer of insulin-like growth factor 1 stimulates proteoglycan synthesis in rabbit joints. Arthritis Rheum. 2000; 43: 2563-70.